- EQS-News: MorphoSys AG: Financial Calendar 2023
- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-DD: MorphoSys AG: Krisja Vermeylen, buy
- EQS-DD: MorphoSys AG: Dr. Marc Cluzel, buy
- EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
- EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
- EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
- EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
- EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
- EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
MorphoSys AG (MOR2:MUN) closed at 3.76, 1.62% above its 52-week low of 3.70, set on Nov 18, 2022.
3.70Nov 18 20229.15Nov 30 2021
Markit short selling activity
|Market cap||545.50m USD|
|EPS (TTM)||-6.52 |
Data delayed at least 15 minutes, as of Nov 29 2022 07:00 GMT.